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Abstract
Background: Osteoporosis is a major health problem worldwide, and is included in the WHO list of the top 10
major diseases. However, it is often undiagnosed until the first fracture occurs, due to inadequate patient
education and lack of insurance coverage for screening tests. Anamnestic risk factors like positive family anamnesis
or early menopause are assumed to correlate with reduced BMD.
Methods: In our study of 78 patients with metaphyseal long bone fractures, we searched for a correlation
between anamnestic risk factors, bone specific laboratory values, and the bone morphogenic density (BMD). Each
indicator was examined as a possible diagnostic instrument for osteoporosis. The secondary aim of this study was
to demonstrate the high prevalence of osteoporosis in patients with metaphyseal fractures.
Results: 76.9% of our fracture patients had decreased bone density and 43.6% showed manifest osteoporosis in DXA
(densitometry) measurements. Our questionnaire, identifying anamnestic risk factors, correlated highly significantly
(p = 0.01) with reduced BMD, whereas seven bone-specific laboratory values (p = 0.046) correlated significantly.
Conclusions: Anamnestic risk factors correlate with pathological BMD. The medical questionnaire used in this
study would therefore function as a cost-effective primary diagnostic instrument for identification of osteoporosis
patients.
Background
The WHO included osteoporosis in the list of the ten
major worldwide diseases [1]. Approximately 200 million
patients worldwide, 44 million in the US and about 7.6
million in Germany, suffer from osteoporosis [2-4]. The
high prevalence of osteoporosis in current populations
becomes more stressing to health care systems as osteo-
porosis rates increase with age, and as populations adopt
unhealthy lifestyles with reduced physical activity and
unbalanced diets [5]. In the western industrial nations
there is an immense imbalance between inadequately
treated osteoporosis and the continually increasing life
expectancies [6]. In Germany, costs incurred due to
osteoporosis result from osteoporosis associated
fractures, especially fractures of proximal femur, and
include acute care, rehabilitation, and extended nursing
care. All in all, the expenditure amounts to 5 billion
euros annually [6,7]. A proximal femur fracture is often
the first indication of manifest osteoporosis. Preventional
diagnostics such as DXA-measuring or laboratory exami-
nation, amounting to approximately 15 million euros per
year, are not currently covered by health insurance.
There are various risk factors, which are assumed to
highly correlate with osteoporosis. These are anamnestic
details of the patient’s medical history as for example:
positive family anamnesis, early menopause, nicotine
abuse, age > 70 years. They are included as osteoporosis-
specific risk factors in the recommendations of the
German Society of Osteology (DVO, Dachverband Osteo-
logie e.V.). The aim of this study is to demonstrate the
high prevalence of osteoporosis in patients with metaphy-
seal fractures, and, secondly, to show the competence of
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Methods
Between January 2008 and May 2010, 78 patients aged 40
to 80 years who presented to our hospital with a meta-
physeal fracture of the distal radius, proximal humerus
and proximal femur with an obligatory indication for sur-
gical stabilization were included in this study. Exclusion
criteria were: polytrauma, significant soft tissue injury,
extensive open fractures, > 24 h mechanical ventilation
after surgery, dialysis, collagenosis, chronic inflammatory
bowel disease, haematological disorders and malignan-
cies, and long-term therapy with immunosuppressants.
X - r a y so ft h ef r a c t u r er e g i o na n dt h el u m b a rs p i n ei n
anterior-posterior and lateral views were performed of all
patients. Lumbar spine radiographs were used to exclude
morphological changes of the vertebrae leading to inaccu-
rate values in DXA bone density measurement. BMD was
examined at the lumbar spine, total hip and hip subregions
using dual energy X-ray absorptiometry DXA (Lunar
iDPX, GE Medical Systems Germany, Solingen, Germany)
based on Encore TM Version II.X software.
Using normative data for young Caucasian adults, BMD
was categorized as normal, low, or osteoporotic, as defined
by the World Health Organization [8]. Participants with a
T-score ≤ -2.5 SD were categorized as having osteoporosis.
To collect the anamnestic risk factors of patients, we
established a standardized questionnaire according to the
recommendations of the German Society of Osteology
(DVO, Dachverband Osteologie e.V.). The questionnaire
included clinical risk factors (19 for men, 21 for women)
as shown in table 1 [9]. The questionnaire was filled out
with one member of the study group present, to provide
assistance if needed.
Laboratory analysis was performed the morning after
injury in a fasting state. Eleven bone specific parameters
reflecting bone metabolism were examined: intact PTH
[10], 25-hydroxy vitamin D3 (25-OH-D3) [11], beta-
crosslaps (ß-CTX), pyridinoline in urine, desoxypyridi-
noline in urine (DPD) [10,12], procollagen type 1 N
propeptide (PINP) [10], creatinine in urine [13], estra-
diol [10], homocysteine, vitamin B12 and folate [14,15].
Every pathologic aberration from the standard value
was assessed with one point.
Statistics were performed using SPSS 11.0.0 (IBM
Germany, Munich, Germany) and Microsoft Excel 2003/
2007 software, Microsoft Corp. Washington, USA. Using
Spearman’s rank correlation coefficient, the single ana-
mnestic risk factors and laboratory parameters were corre-
lated with the reduced BMD values. P ≤ 0.05 was
considered to be significant and p ≤ 0.01 highly significant.
In addition we performed a multivariable analysis in order
to adjust for potential confounders. With the method of
“ordinal logistic regression” we examined age, sex and BMI
as possible confounders with the variables BMD, risk fac-
tors and laboratory values.
The study is approved by the local Ethical Committee
of Heidelberg with the approval number 1572002. All
patients gave their informed consent prior to their
inclusion in the study.
Results
A total of 78 patients who suffered a metaphyseal frac-
ture of the distal radius, proximal humerus or proximal
femur between January 2008 and May 2010 were
included in this study. The average patient age was 62.2
years with a range from 41.9 to 77.6 years. The 12 male
patients had an average age of 65.4 years, the 66 female
patients of 61.6 years. 41 patients had a distal radius
fracture, 23 patients a proximal humerus fracture and
14 patients suffered a proximal femur fracture.
In DXA-measuring 76.9% of patients showed a patholo-
gic bone density. 34 (43.6%) patients had a decrease in
bone density in terms of osteoporosis, 26 (33.3) patients
had osteopenic BMD. 18 (23.1%) of patients had physiolo-
gical findings (Figure 1). Among the male patients, 58.3%
showed manifest osteoporosis and 16.7% osteopenia.
Table 1 Medical questionnaire of anamnestic risk factors
for reduced BMD
men women total
Reduction of body height > 4 cm 391 2
Alcohole abuse 246
Age > 70 21 41 6
Anorexia nervosa 000
Anticonvulsive therapy 101
Already suffered osteoporotic fractures 291 1
BMI < 20 kg/m
2 000
Chronical renal or hepatic disease 022
Family history 31 92 2
Early menopause (< 45. Lj.) -1 3 1 3
Late menarche (> 15. Lj.) -22
Highdose heparintherapy 011
Hormon replacement therapy 066
Hyperparathyroidism 000
Hyperthyroidism 044
(N)IDDM 134
Immobilisation, Inactivity 112
Malabsorption-syndrome 000
Multiple Sclerosis 011
Nikotine abuse 31 21 5
Rheumatoid Arthritis 044
The right columns show the frequence of aberrations of the single risk factors
in our study.
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and in 36.4% an osteopenia.
The frequency of the single anamnestic risk factors can
be seen in table 1. The leading risk factors are: positive
family history, age > 70 years, nicotine abuse, early meno-
pause, reduction of body height > 4 cm and previous
osteoporotic fractures. There was no incident of 4 risk
factors (anorexia nervosa, BMI < 20 kg/m
2, hyperparathyr-
eoidism, malabsorption syndrome) in our collective.
Questionnaire risk factors correlated with reduced
bone density values. Spearman’s rank correlation allowed
separate consideration of the individual risk factors
reduced bone density. The 10 anamnestic risk factors:
reduce of body height > 4 cm, alcohol abuse, age > 70
years, anticonvulsant therapy, previous osteoporotic frac-
tures, early menopause (< 45years), hyperthyroidism,
immobilization, multiple sclerosis and nicotine abuse
showed a highly significant correlation (p = 0.01) with
low bone density (Figure 2).
Table 2 shows the frequency of pathological laboratory
values in our collective. Laboratory values of 67 patients
were evaluated; 11 patients declined blood sample collec-
tion. The main pathologic laboratory values are: homocys-
teine (51 patients), 25-OH-D3 (42 patients), and
desoxypyridinoline (31 Patients). The fewest aberrations
were seen in ß-CTX (13 patients), estradiol (7 patients)
and vitamin B12 (6 Patients) measurings.
For statistical analyses, Spearman’s rank was used to
correlate abnormal laboratory values with a decrease in
bone density. The highest correlation (p = 0.046) was
noted in parathyroid hormone, 25-OH-D3, procollagen
type 1 N propeptide, desoxypyridinoline, creatinine,
homocysteine and vitamin B12 (Figure 3).
The multivariable analysis showed no significant
effects with the variables; thus the age, sex and BMI of
patient do not have a confounding effect.
Discussion
In this study, nearly 80% of patients who suffered a
metaphyseal fracture showed pathologically reduced
bone mineral density, and nearly 50% of the patients
were diagnosed with manifest osteoporosis. 84.6% of our
men  women 
healthy 
osteopenia 
osteoporosis 
Figure 1 Results of DXA-measuring. Percentaged amount of healthy, osteopenic and osteoporotic values in women and men.
 
 
Number of anamnestic risk factors 
Lowest T-values in DXA-measuring
Figure 2 Diagram presenting the correlation between the
lowest T-values of DXA-measuring with increasing number of
anamnestic risk factors. The correlation of the most important risk
factors and a reduced BMD is highly significant (p = 0.01,
Spearman’s rank correlation).
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cide with current research; Vogel et al. [16] found osteo-
porosis in 72% of acute limb fracture patients (only 4%
showed normal bone density). Another Dutch study [17]
evaluated fractures resulting from low energy trauma
and found manifest osteoporosis in 67% of patients.
(Hegemann et al defined the T-Score as < -2.0 for
osteoporosis, compared to < -2.5 in our study).
Having identified one of the major problems in treat-
ment of osteoporosis: post fracture diagnosis; we have
identified the major cause of the progression of this dis-
ease: the therapeutic window in which to minimize frac-
ture risk is overlooked. Due to the exceptionally high
morbidity and mortality after osteoporotic fractures, pre-
vention is essential. However, as mentioned, the costs for
preventional screenings such as DXA-measurement or
laboratory examination (amounting to approximately
15 million euros per year) are not currently covered by
German health insurance companies [6]. Furthermore,
bone loss progresses silently, and without patient educa-
tion and preventional screenings, few patients would
recognize the risk [18,19].
A safe, simple and cost effective instrument for osteo-
porosis diagnosis is essential. The results of this study
show that a simple medical questionnaire containing 10
anamnestic questions is a reliable test to quickly and
efficiently screen large numbers of patients for reduced
BMD. With early detection of bone loss and consecutive
implementation of antiosteoporotic therapy, the risk of
osteoporotic fractures with the coinciding high morbid-
ity and mortality can be reduced, thereby achieving a
massive decrease in health care costs.
The most important risk factors identified by the
questionnaire are as follows:
Patient age represents a core variable for osteoporosis
risk [20] increasing age increases fracture risk [8,21].
Age related decreases in estrogen lead to disrupted
microarchitecture of trabecular bone [22]. Thus, age is
one of the most important risk factors for osteoporosis
and therefore was included in the DVO.
The loss of ≥ 4c mb o d yh e i g h ti sr i s kf a c t o rf o r
reduced BMD, and may result from vertebral sintering
due to osteoporotic change of trabecular structure. Joa-
kimsen et al. [23] showed that patients with a maximal
height of 168 cm suffered fracture of the lower extre-
mity 2.5 times more often.
Excessive alcohol consumption showed high signifi-
cance with reduced BMD in our study. Kanis et al. [24]
also demonstrated a correlation between high amounts
of alcohol consumption and reduced BMD. The cause
may be increased renal secretion of calcium. On the
other hand, low alcohol consumption (one glass of wine
per day) can positively influence bone mineral density
[25].
Similar osteoporotic findings exist for nicotine abu-
sers, due to a reduced enteral resorption of calcium
[26]. Comparing smokers and non-smokers Kanis et al.
[24] showed a significantly increased fracture rate in
smokers. In addition, Law et al. [27] found out that the
risk of bone loss caused by smoking is especially high in
postmenopausal women over the age of 60.
In the past, the high fracture rate under epileptic
patients was explained by the convulsive seizures; how-
ever, the anticonvulsive pharmaceuticals are now known
to reduce the enteral resorption of calcium, and thereby
causing the high prevalence of reduced bone density
found in this population [28-30].
Early menopause, before age 45, is also defined as a
risk factor for decreasing bone mass. The comparatively
short estrogen exposition time is thought to enhance
bone resorption [31]. Other authors propose nutrition
as the cause [32].
Table 2 Frequence of aberrations of bone specific
laboratory parameters in women, men and in total
men women total
Parathormone intakt 52 22 7
25 (OH) D3 73 54 2
ß-CTX 21 11 3
Pyridinoline (urine) 42 52 9
Procollagen Typ I N propeptide 11 41 5
Desoxypyridinoline (urine) 42 73 1
Creatinine (urine) 61 21 8
Estradiol 167
Homocysteine 74 45 1
Vitamin B12 246
Folate 32 22 5
 
Number of pathologic laboratory values 
Lowest T-values in DXA-measuring 
Figure 3 Diagram presenting the correlation between the
lowest T-values of DXA-measuring with increasing number of
pathologic laboratory parameters. The correlation of the seven
bone specific values and a reduced BMD is significant (p = 0.046,
Spearman’s rank correlation).
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leads to a decreased bone mineral density [33,34]. Postme-
nopausal women with hyperthyroidism are especially vul-
nerable to bone mass loss [35]. The mechanism of action
has been proposed by Katani et al. [36] and [37] Garnero
et al. to be trijodthyronine (T3) induction of differentiation
of osteoclasts. This leads to the creation of bone resorp-
tion products (e.g. pyridinoline, peptides of collagen) and
excretion of calcium in the urine. T3 also stimulates osteo-
blasts, but all in all the balance is negative.
Another highly significant factor in our study was the
immobilisation or inactivity of patients. Also Dargent-
Moline [38] showed that a reduced mobility, activity and
reduced musculature increases the risk of developing
osteoporosis. Due to the missing mechanical exposure of
the muscular-skeletal system, the bone tissue weakens
[39]. This explains why patients with multiple sclerosis
suffer a significantly reduced bone mineral density [40].
Our questionnaire represents a screening method; if
reduced BMD is suggested, a complete diagnosis with clin-
ical examination, laboratory tests, radiography and DXA
measurement remain the gold standard to achieve a pre-
cise diagnosis of the extent, cause, and indicated treatment
of pathological bone density.
As for the bone specific laboratory values, out of the
11 factors examined in this study, 7 showed a significant
correlation to a reduced BMD, and are discussed below.
Most of our patients showed a lack of 25-OH vitamin
D3, probably due to the reduced exposure to sunlight dur-
ing winter. The lack of D3 leads to PTH increase which
induces calcium decomposition in bone; possibly the
cause of the high PTH levels found in our patients.
Another cause of elevated PTH is primary or secondary
hyperthyroidism [41-43]. Both low D3 and high PTH are
important parameters in the diagnosis and treatment of
osteoporosis in the DVO guidelines [9].
One of the most significant markers for osteoblast activ-
ity is the PINP (procollagen type 1 N propeptide), which is
separated during synthesis of collagen. Increased values
indicate active bone formation, and is typical for malignant
tumors or osteoporosis [12,44,45].
Desoxypyridinoline is a decomposition product of col-
lagene and represents a specific marker for osteoclast
activity. Various studies proved its reliability [46-48].
Creatinine levels detect secondary osteoporosis due to
renal osteopathy. Homocysteine is mainly used for the
identification of an atherosclerotic risk profile. Increased
blood levels of homocysteine in conjunction with
decreased vitamin B12, leads to a reduced BMD and, as
reported by Leboff et al. [49] results in osteoporotic frac-
tures. Further studies presented same findings [50,51].
Stimulation of osteoclast activity is presumed to be the
mechanism by which a high level of homocysteine and a
low level of vitamin B12 reduces of BMD [52].
Conclusions
In conclusion, there is a high prevalence of undiagnosed
osteopenia and osteoporosis in patients suffering metaphy-
seal fractures. Both methods (medical questionnaire and
laboratory analysis) examined in our study present reliable
instruments for diagnostics of osteoporosis. Astonishingly,
the cost-effective and “simple” medical questionnaire
showed a high correlation with reduced BMD and there-
with presents next to the laboratory values a powerful
instrument for osteoporosis diagnostics.
Integrity of research and reporting
The study is approved by the local Ethical Committee of
Heidelberg with the approval number 1572002. All
patients gave their informed consent prior to their
inclusion in the study.
Author details
1Department for Plastic-, Reconstructive and Handsurgery, Burn Care Centre,
BG Unfallklinik Ludwigshafen, Ludwig-Guttmann-Str.13, 67071 Ludwigshafen,
Germany.
2Department of Trauma and Orthopaedic Surgery, BG Trauma
Center Ludwigshafen, Ludwig-Guttmann-Str.13, 67071 Ludwigshafen,
Germany.
3Clinical Laboratory Limbach, Im Breitspiel 15, 69126 Heidelberg,
Germany.
4Department of Social and Legal Sciences, SRH Hochschule
Heidelberg, Ludwig-Guttmann-Str.6, 69123 Heidelberg, Germany.
Authors’ contributions
LK participated in the evaluation of patients, data, statistics and wrote the
paper, she has seen and approved the final version. CT participated in
planning of the study, evaluation of patients and data and has seen and
approved the final version. AM participated in planning of the study,
evaluation of patients, data and statistics and has seen and approved the
final version. MH participated in planning of the study, evaluation of patients
and data and has seen and approved the final version. AS participated in
planning of the study, evaluation of patients, data and statistics and has
seen and approved the final version. HS-G participated essentially in
establishment of laboratory analyses, their evaluation and statistics, but
unfortunately died before submission of this study. BH participated
substancially in planning of the study and performing of statistics and has
seen and approved the final version. PAG participated in planning of the
study, supervision of the study, evaluation of patients, data and statistics and
has seen and approved the final version. CW participated substancially in
planning of the study, supervision of the study, evaluation of patients, data
and statistics and has seen and approved the final version.
Competing interests
The authors declare that they have no competing interests.
Received: 6 March 2011 Accepted: 17 August 2011
Published: 17 August 2011
References
1. Macdonald HM, New SA, Campbell MK, Reid DM: Influence of weight and
weight change on bone loss in perimenopausal and early
postmenopausal Scottish women. Osteoporos Int 2005, 16:163-171.
2. Cooper C: Epidemiology of osteoporosis. Osteoporos Int 1999, 9-2:2-8.
3. Reginster JY, Burlet N: Osteoporosis: a still increasing prevalence. Bone
2006, 38:4-9.
4. Haussler B, Gothe H, Gol D, Glaeske G, Pientka L, Felsenberg D:
Epidemiology, treatment and costs of osteoporosis in Germany-the
BoneEVA Study. Osteoporos Int 2007, 18:77-84.
5. Macdonald HM, New SA, Golden MH, Campbell MK, Reid DM: Nutritional
associations with bone loss during the menopausal transition: evidence
of a beneficial effect of calcium, alcohol, and fruit and vegetable
Kolios et al. BMC Musculoskeletal Disorders 2011, 12:187
http://www.biomedcentral.com/1471-2474/12/187
Page 5 of 7nutrients and of a detrimental effect of fatty acids. Am J Clin Nutr 2004,
79:155-165.
6. Minne HW, Pfeifer M, Begerow B, Pollahne W: Osteoporosis. Orthopade
2002, 31:681-979.
7. Gotte S, Dittmar K: Epidemiology and costs of osteoporosis. Orthopade
2001, 30:402-404.
8. Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B: Ten year
probabilities of osteoporotic fractures according to BMD and diagnostic
thresholds. Osteoporos Int 2001, 12:989-995.
9. Pfeilschifter J: Osteoporosis-current diagnostics and therapy. Med Klin
(Munich) 2009, 104:632-643.
10. Guder WG, Nolte J: Das Laborbuch für Klinik und Praxis. First ed Munich
2005, Elsevier.
11. Ledger GA, Burritt MF, Kao PC, O’Fallon WM, Riggs BL, Khosla S: Role of
parathyroid hormone in mediating nocturnal and age-related increases
in bone resorption. J Clin Endocrinol Metab 1995, 80:3304-3310.
12. Christenson RH: Biochemical markers of bone metabolism: an overview.
Clin Biochem 1997, 30:573-593.
13. Kansal S, Fried L: Bone disease in elderly individuals with CKD. Adv
Chronic Kidney Dis 2010, 17:41-51.
14. Tucker KL, Hannan MT, Qiao N, Jacques PF, Selhub J, Cupples LA, Kiel DP:
Low plasma vitamin B12 is associated with lower BMD: the Framingham
Osteoporosis Study. J Bone Miner Res 2005, 20:152-158.
15. Holstein JH, Herrmann M, Splett C, Herrmann W, Garcia P, Histing T,
Graeber S, Ong MF, Kurz K, Siebel T, Menger MD, Pohlemann T: Low serum
folate and vitamin B-6 are associated with an altered cancellous bone
structure in humans. Am J Clin Nutr 2009, 90:1440-1445.
16. Vogel T, Dobler T, Bitterling H, Biberthaler P, Kanz KG, Pfeifer KJ, Bartl R,
Mutschler W: Osteoporosis in traumatology. Prevalence and
management. Unfallchirurg 2005, 108:356-364.
17. Hegeman JH, Willemsen G, Van Nieuwpoort J, Kreeftenberg HG, Van Der
Veer E, Slaets JP, Ten Duis HJ: Effective tracing of osteoporosis at a
fracture and osteoporosis clinic in Groningen; an analysis of the first 100
patients. Ned Tijdschr Geneeskd 2004, 148:2180-2185.
18. Brask-Lindemann D, Cadarette SM, Eskildsen P, Abrahamsen B:
Osteoporosis pharmacotherapy following bone densitometry:
importance of patient beliefs and understanding of DXA results.
Osteoporos Int 2010.
19. Berry SD, Misra D, Hannan M, Kiel DP: Low acceptance of Treatment in
the Elderly for the Secondary Prevention of Osteoporotic Fracture in the
Acute Rehabilitation Setting. Aging Clin Exp Res 2010, 22:231-237.
20. Wehren LE, Siris ES: Beyond bone mineral density: can existing clinical
risk assessment instruments identify women at increased risk of
osteoporosis? J Intern Med 2004, 256:375-380.
21. Ismail AA, Pye SR, Cockerill WC, Lunt M, Silman AJ, Reeve J, Banzer D,
Benevolenskaya LI, Bhalla A, Bruges Armas J, Cannata JB, Cooper C,
Delmas PD, Dequeker J, Dilsen G, Falch JA, Felsch B, Felsenberg D, Finn JD,
Gennari C, Hoszowski K, Jajic I, Janott J, Johnell O, Kanis JA, Kragl G, Lopez
Vaz A, Lorenc R, Lyritis G, Marchand F, Masaryk P, Matthis C, Miazgowski T,
Naves-Diaz M, Pols HA, Poor G, Rapado A, Raspe HH, Reid DM, Reisinger W,
Scheidt-Nave C, Stepan J, Todd C, Weber K, Woolf AD, O’Neill TW:
Incidence of limb fracture across Europe: results from the European
Prospective Osteoporosis Study (EPOS). Osteoporos Int 2002, 13:565-571.
22. Cadarette SM, Jaglal SB, Kreiger N, Mcisaac WJ, Darlington GA, Tu JV:
Development and validation of the Osteoporosis Risk Assessment
Instrument to facilitate selection of women for bone densitometry. CMAJ
2000, 162:1289-1294.
23. Joakimsen RM, Fonnebo V, Magnus JH, Tollan A, Sogaard AJ: The Tromso
Study: body height, body mass index and fractures. Osteoporos Int 1998,
8:436-442.
24. Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B,
Oden A, Zethraeus N, Pfleger B, Khaltaev N: Assessment of fracture risk.
Osteoporos Int 2005, 16:581-589.
25. Bainbridge KE, Sowers M, Lin X, Harlow SD: Risk factors for low bone
mineral density and the 6-year rate of bone loss among premenopausal
and perimenopausal women. Osteoporos Int 2004, 15:439-446.
26. Krall EA, Dawson-Hughes B: Smoking increases bone loss and decreases
intestinal calcium absorption. J Bone Miner Res 1999, 14:215-220.
27. Law MR, Hackshaw AK: A meta-analysis of cigarette smoking, bone
mineral density and risk of hip fracture: recognition of a major effect.
BMJ 1997, 315:841-846.
28. Vestergaard P, Rejnmark L, Mosekilde L: Fracture risk associated with use
of antiepileptic drugs. Epilepsia 2004, 45:1330-1337.
29. Petty SJ, O’Brien TJ, Wark JD: Anti-epileptic medication and bone health.
Osteoporos Int 2007, 18:129-142.
30. Schmitz B: Depression and mania in patients with epilepsy. Epilepsia
2005, 46-4:45-49.
31. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE,
Cauley J, Black D, Vogt TM: Risk factors for hip fracture in white women.
Study of Osteoporotic Fractures Research Group. N Engl J Med 1995,
332:767-773.
32. Van Der Klift M, De Laet CE, McCloskey EV, Johnell O, Kanis JA, Hofman A,
Pols HA: Risk factors for incident vertebral fractures in men and women:
the Rotterdam Study. J Bone Miner Res 2004, 19:1172-1180.
33. Belaya ZE, Melnichenko GA, Rozhinskaya LY, Fadeev VV, Alekseeva TM,
Dorofeeva OK, Sasonova NI, Kolesnikova GS: Subclinical hyperthyroidism of
variable etiology and its influence on bone in postmenopausal women.
Hormones (Athens) 2007, 6:62-70.
34. Morris MS: The association between serum thyroid-stimulating hormone
in its reference range and bone status in postmenopausal American
women. Bone 2007, 40:1128-1134.
35. Biondi B, Palmieri EA, Klain M, Schlumberger M, Filetti S, Lombardi G:
Subclinical hyperthyroidism: clinical features and treatment options. Eur
J Endocrinol 2005, 152:1-9.
36. Kanatani M, Sugimoto T, Sowa H, Kobayashi T, Kanzawa M, Chihara K:
Thyroid hormone stimulates osteoclast differentiation by a mechanism
independent of RANKL-RANK interaction. J Cell Physiol 2004, 201:17-25.
37. Garnero P, Vassy V, Bertholin A, Riou JP, Delmas PD: Markers of bone
turnover in hyperthyroidism and the effects of treatment. J Clin
Endocrinol Metab 1994, 78:955-959.
38. Dargent-Molina P, Poitiers F, Breart G: In elderly women weight is the best
predictor of a very low bone mineral density: evidence from the EPIDOS
study. Osteoporos Int 2000, 11:881-888.
39. Bauman WA, Spungen AM, Wang J, Pierson RN, Schwartz E: Continuous
loss of bone during chronic immobilization: a monozygotic twin study.
Osteoporos Int 1999, 10:123-127.
40. Hearn AP, Silber E: Osteoporosis in multiple sclerosis. Mult Scler 2010,
16:1031-1043.
41. Binkley N, Ramamurthy R, Krueger D: Low vitamin D status: definition,
prevalence, consequences, and correction. Endocrinol Metab Clin North
Am 2010, 39:287-301.
42. Sitges-Serra A, Garcia L, Prieto R, Pena MJ, Nogues X, Sancho J: Effect of
parathyroidectomy for primary hyperparathyroidism on bone mineral
density in postmenopausal women. Br J Surg 2010, 97:1013-1019.
43. Giusti A, Barone A, Pioli G, Girasole G, Razzano M, Pizzonia M, Pedrazzoni M,
Palummeri E, Bianchi G: Heterogeneity in Serum 25-Hydroxy-Vitamin D
Response to Cholecalciferol in Elderly Women with Secondary
Hyperparathyroidism and Vitamin D Deficiency. J Am Geriatr Soc 2010,
58:1489-1495.
44. Diaz-Martin MA, Traba ML, De La Piedra C, Guerrero R, Mendez-Davila C, De
La Pena EG: Aminoterminal propeptide of type I collagen and bone
alkaline phosphatase in the study of bone metastases associated with
prostatic carcinoma. Scand J Clin Lab Invest 1999, 59:125-132.
45. Garnero P, Vergnaud P, Hoyle N: Evaluation of a fully automated serum
assay for total N-terminal propeptide of type I collagen in
postmenopausal osteoporosis. Clin Chem 2008, 54:188-196.
46. Nishizawa Y, Nakamura T, Ohta H, Kushida K, Gorai I, Shiraki M, Fukunaga M,
Hosoi T, Miki T, Chaki O, Ichimura S, Nakatsuka K, Miura M: Guidelines for
the use of biochemical markers of bone turnover in osteoporosis (2004).
J Bone Miner Metab 2005, 23:97-104.
47. Raisz LG: Clinical practice. Screening for osteoporosis. N Engl J Med 2005,
353:164-171.
48. Seibel MJ: Clinical use of markers of bone turnover in metastatic bone
disease. Nat Clin Pract Oncol 2005, 2:504-517.
49. Leboff MS, Narweker R, Lacroix A, Wu L, Jackson R, Lee J, Bauer DC,
Cauley J, Kooperberg C, Lewis C, Thomas AM, Cummings S: Homocysteine
levels and risk of hip fracture in postmenopausal women. J Clin
Endocrinol Metab 2009, 94:1207-1213.
50. Yilmaz N, Eren E: Homocysteine oxidative stress and relation to bone
mineral density in post-menopausal osteoporosis. Aging Clin Exp Res
2009, 21:353-357.
Kolios et al. BMC Musculoskeletal Disorders 2011, 12:187
http://www.biomedcentral.com/1471-2474/12/187
Page 6 of 751. Krivosikova Z, Krajcovicova-Kudlackova M, Spustova V, Stefikova K,
Valachovicova M, Blazicek P, Nemcova T: The association between high
plasma homocysteine levels and lower bone mineral density in Slovak
women: the impact of vegetarian diet. Eur J Nutr 2010, 49:147-153.
52. Herrmann M, Joseph J, Tyagi SC: Homocysteine, brain natriuretic peptide
and chronic heart failure: a critical review. Clin Chem Lab Med 2007,
45:1633-1644.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2474/12/187/prepub
doi:10.1186/1471-2474-12-187
Cite this article as: Kolios et al.: Anamnestic risk factor questionnaire as
reliable diagnostic instrument for osteoporosis (reduced bone
morphogenic density). BMC Musculoskeletal Disorders 2011 12:187.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Kolios et al. BMC Musculoskeletal Disorders 2011, 12:187
http://www.biomedcentral.com/1471-2474/12/187
Page 7 of 7